AbbVie began another round of layoffs tied to its Allergan footprint, issuing a WARN notice for 85 permanent job cuts at its Irvine, California site. The company framed the actions within its eye care business and indicated the reductions would take effect July 20. AbbVie acquired Allergan in 2019, integrating products including Botox and expanding its ophthalmology portfolio. The layoff sequence comes as the Allergan segment has seen revenue swings, including a recent quarter showing growth after prior declines. The operational shift also matters for development capacity: the Irvine campus is described as a center of excellence spanning aesthetics, neurotoxins, migraine, and eye care research, so staffing changes can affect pipeline execution and manufacturing-linked programs.